摘要
目的:通过网络药理学探索益肾化瘀方延缓肾间质纤维化(RIF)的分子机制,并进行实验验证。方法:利用网络药理学获取益肾化瘀方延缓RIF可能的作用机制,并进行分子对接验证其结合力。构建RIF小鼠模型,观察益肾化瘀方对肾组织病理损伤以及Bax、Bcl-2表达的影响。结果:网络药理学研究显示益肾化瘀方可通过多靶点干预RIF,其作用机制可能与细胞凋亡等通路相关。分子对接显示益肾化瘀方活性成分与防治RIF共有靶点的结合活性较好。动物实验显示,益肾化瘀方可降低RIF小鼠肾组织细胞凋亡水平,改善肾小管损伤,显著降低肾组织Bax、Bcl-2表达(P<0.01),进而减轻RIF。结论:益肾化瘀方可以干预多种RIF基因,其保护作用机制可能与下调细胞凋亡有关。
Objective:To explore the molecular mechanism of Yishen Huayu Formula in delaying renal interstitial fibrosis(RIF)through network pharmacology,and to carry out experimental verification.Methods:Using network pharmacology to obtain the possible mechanism of Yishen Huayu Formula in delaying RIF,and conduct molecular docking to verify its binding force.To establish the model of RIF in mice and observe the effect of Yishen Huayu Formula on renal tissue pathological injury and expression of Bax and Bcl-2.Results:Network pharmacology studies had shown that Yishen Huayu Formula could intervene in RIF through multiple targets,and its mechanism of action may be related to pathways such as cell apoptosis.Molecular docking showed that the active components of Yishen Huayu Formula had better binding activity with common targets for prevention and treatment of RIF.Animal experiments showed that Yishen Huayu Formula could reduce the level of apoptosis of renal tissue cells,improve the damage of renal tubules,significantly reduce the expression of Bax and Bcl-2 in renal tissue(P<0.01),thereby alleviate RIF.Conclusion:Yishen Huayu Formula can interfere with a variety of RIF genes,and its renal protective mechanism may be related to the down regulation of apoptosis.
作者
陈旭
王希茜
张琳琪
CHEN Xu;WANG Xixi;ZHANG Linqi(Henan University of Chinese Medicine,Zhengzhou 450046,China;The First Affiliated Hospital of Henan University of CM,Zhengzhou 450000,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2024年第2期973-978,共6页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
国家自然科学基金面上项目(No.81973806)
河南省中医药科学研究专项课题重大专项基金(No.2019ZYZD05)
河南省中原千人计划-中原名医项目(No.ZYYCYU202012120)。
关键词
益肾化瘀方
肾间质纤维化
网络药理学
分子对接
实验验证
机制
Yishen Huayu Formula
Renal interstitial fibrosis(RIF)
Network pharmacology
Molecular docking
Experimental verification
Mechanism